RxDoctor Payments Data

Thomas Pugh, MD

Radiation Oncology · Denver, CONPI 1174679799

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $12,172 of the $14,785 with a category attached, or 82.3%. Boston Scientific accounts for 97.0% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2022 at $8,938 and has fallen 99.7% since, to $23 in 2025. Among radiation oncology clinicians in CO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$14,785in general payments, 2019–2025

Across 45 payments — averaging $328.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$14K
  • Myovant Sciences Inc.$93
  • Telix Pharmaceuticals$91
  • Astellas Pharma US Inc$86
  • Sumitomo Pharma America, Inc.$53
  • Siemens Medical Solutions USA, Inc.$42
  • plus $81 from 4 others
$102,354in research payments, 2019–2025

Across 39 payments — averaging $2624.45 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Janssen Research & Development, LLC$102K

What the payments were for

  • Consulting fees$1,63511%
  • Speaking & faculty fees$12,17282%
  • Food & beverage$9797%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,785 in reported general payments places this provider in the 90th percentile of 105 radiation oncology providers in Colorado.

See all radiation oncology providers in Colorado

Medicare billing

Part B allowed, 2024
$270,637
Medicare patients
221
Services billed
2,375

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Tamsulosin Hcl213$2,659
Methylprednisolone99$642

Paid to pharmacies, not to this prescriber.

Other radiation oncology in Denver

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →